On an Inherited Autosomal Hemorrhagic Diathesis with Antihemophilic Globulin (AHG) Deficiency and Prolonged Bleeding Times<sup>1</sup>

Nilsson, Inga Marie; Blombäck, Margareta; Francken, Irene V.

doi:10.1111/j.0954-6820.1957.tb00532.x

Cited by 298 publications

(55 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prior to the first trip in 1957, Inga Marie Nilsson and I had investigated many Swedish families with “pseudohemophilia” and found low FVIII and a prolonged bleeding time . In addition, Birger Blombäck and I had purified a plasma fraction (Fraction I‐0) that contained fibrinogen and FVIII, which stopped bleeding in patients with VWD, normalized FVIII and corrected the prolonged bleeding time .…”

Section: Memories Of Margareta Blombäck On Research On/about åLand Anmentioning

confidence: 99%

Fifth Åland Island conference on von Willebrand disease

et al. 2018

View full text Add to dashboard Cite

The fifth Åland Island meeting on von Willebrand disease (VWD) was held on the Åland Islands, Finland, from 22 to 24 September 2016-90 years after the first case of VWD was diagnosed in a patient from the Åland Islands in 1926. This meeting brought together experts in the field of VWD to share knowledge and expertise on current trends and challenges in VWD. Topics included the storage and release of von Willebrand factor (VWF), epidemiology and diagnostics in VWD, treatment of VWD, angiogenesis and VWF inhibitors.

show abstract

Section: Memories Of Margareta Blombäck On Research On/about åLand Anmentioning

confidence: 99%

Fifth Åland Island conference on von Willebrand disease

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Most pharmacokinetic studies have been performed in patients who are either adult or adolescent and the change in pharmacokinetic parameters from childhood up to adult age has not been studied. It is known that some concentrates give a pronounced secondary rise of FVIII after infusion and this was demonstrated in the 1950s using Cohn fraction I‐O . The complicated pharmacokinetics means that it not so worthwhile to perform presurgical pharmacokinetic analysis in order to direct dosing .…”

Section: A Lifespan Of Pharmacokinetics In Vwdmentioning

confidence: 99%

Third Åland islands conference on vonWillebrand disease, 26–28September 2012: meeting report

Berntorp

Fuchs²,

Makris

et al. 2013

Haemophilia

View full text Add to dashboard Cite

Summary The first meeting of international specialists in the field of von Willebrand disease (VWD) was held in the Åland islands in 1998 where Erik von Willebrand had first observed a bleeding disorder in some members of a family from Föglö and a summary of the meeting was published in 1999. The second meeting was held in 2010 and a report of the meeting was published in 2012. Topics covered included progress in understanding of VWD over the last 50 years; multimers; classification of VWD; pharmacokinetics and laboratory assays; genetics; treating the paediatric patient; prophylaxis; geriatrics; gene therapy and treatment guidelines. This third meeting held over 3 days covered the structure and function of von Willebrand factor (VWF); type 1 VWD, the most common form of the disease; a lifespan of pharmacokinetics in VWD; detecting inhibitors in VWD patients; and special challenges in understanding and treating the female VWD patient.

show abstract

“…1 It took another 30 years before the plasma protein that is central to the disease was identified, and this was eponymously named von Willebrand factor (VWF). 2,3 Since then, much of the structure and function of VWF have been elucidated, and insights into the pathology of von Willebrand disease (VWD) have been continuously gained. This has naturally led to the development of improved treatment strategies for this sometimes life-threatening disorder.…”

Section: Introductionmentioning

confidence: 99%